CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting ...Middle East

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Hematology (the "ASH")...

Hence then, the article about carsgen presents data from china pivotal phase ii trial of bcma car t zevor cel ct053 at 2022 ash annual meeting was published today ( Monday 12/12/2022 - 05:08 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( CARsgen Presents Data from China Pivotal Phase II Trial of BCMA CAR T Zevor-cel (CT053) at 2022 ASH Annual Meeting )

Also on site :

• HBO Max Moves Up Forthcoming Episodes Of ‘Industry,’ ‘A Knight Of The Seven Kingdoms’ Ahead Of Super Bowl
• Why Did Taylor Swift Skip the 2026 Grammy Awards? Fans Are Disappointed
• Donald Trump Slams Grammys as ‘Unwatchable’ and Calls Trevor Noah a ‘Total Loser’ Over Trump-Epstein Island Joke: ‘It Looks Like I’ll Be Sending My Lawyers to Sue This Pathetic Dope’